GlycoMimetics (NASDAQ:GLYC) issued its quarterly earnings results on Sunday. The biotechnology company reported ($0.28) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.04, MarketWatch Earnings reports.
Shares of NASDAQ:GLYC traded down $0.08 during mid-day trading on Tuesday, hitting $2.32. 9,822 shares of the company traded hands, compared to its average volume of 806,132. The firm’s 50 day simple moving average is $2.90 and its 200 day simple moving average is $3.43. The firm has a market cap of $119.57 million, a P/E ratio of -2.06 and a beta of 2.46. GlycoMimetics has a 52-week low of $2.31 and a 52-week high of $5.19.
A number of equities research analysts recently issued reports on GLYC shares. Zacks Investment Research upgraded shares of GlycoMimetics from a “sell” rating to a “hold” rating in a report on Friday, March 5th. Stifel Nicolaus increased their target price on shares of GlycoMimetics from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of GlycoMimetics in a research report on Wednesday, March 10th.
GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease.
Further Reading: What are catch-up contributions?
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.